Abstract LB-327: Loss of PTEN leads to clinical resistance to the PI3Kα inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure | Citedby Results | Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Abstract LB-327: Loss of PTEN leads to clinical resistance to the PI3Kα inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure

Cancer Res (2014) 74 (19_Supplement): LB-327.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic

Aglaia Skolariki
Jamie D’Costa
Martin Little
Simon Lord

Exploration of Targeted Anti-tumor Therapy 172.

Molecular profiling of head and neck squamous cell carcinoma

Rebecca Feldman
Zoran Gatalica
Joseph Knezetic
Sandeep Reddy
Cherie‐Ann Nathan
Nader Javadi
Theodoros Teknos

Head & Neck (2016) 38 (S1)

Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition

Cedric Leroy
Pedro Ramos
Karen Cornille
Debora Bonenfant
Christine Fritsch
Hans Voshol
Mohamed Bentires-Alj

Breast Cancer Research (2016) 18 (1)

Targeting PI3‐kinase (PI3K), AKT and mTOR axis in lymphoma

James S. Blachly
Robert A. Baiocchi

British Journal of Haematology (2014) 167 (1): 19.